TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Stock
Certificat
DE000SD81XH8
| Delayed Deutsche Boerse AG 13:53:06 2024-05-31 EDT | ||
| 4.91 EUR | +3.59% |
|
| Current month | -2.07% | ||
| 1 month | -2.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 4.91 | +3.59% |
| 24-05-30 | 4.74 | +2.38% |
| 24-05-29 | 4.63 | -2.11% |
| 24-05-28 | 4.73 | -7.62% |
| 24-05-27 | 5.12 | +1.39% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 01:53 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD81XH |
| ISIN | DE000SD81XH8 |
| Date issued | 2021-03-15 |
| Strike | 8,019 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.58 € |
|---|---|
| Lowest since issue | 0.19 € |
| Spread | 0.08 € |
| Spread % | 1.60% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
